Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose.
Peterson J, Drazan D, Moughan B, Maguire JD, Zolotas L, Maansson R, O'Neill R, Peyrani P, Jodar L, Gruber WC, Anderson AS, Beeslaar J. Peterson J, et al. Among authors: jodar l. Vaccine. 2025 Jan 1;43(Pt 1):126469. doi: 10.1016/j.vaccine.2024.126469. Epub 2024 Nov 8. Vaccine. 2025. PMID: 39520893 Free article. Clinical Trial.
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.
Sabharwal C, Sundaraiyer V, Peng Y, Moyer L, Belanger TJ, Gessner BD, Jodar L, Jansen KU, Gruber WC, Scott DA, Watson W. Sabharwal C, et al. Among authors: jodar l. Hum Vaccin Immunother. 2022 Nov 30;18(6):2126253. doi: 10.1080/21645515.2022.2126253. Epub 2022 Nov 11. Hum Vaccin Immunother. 2022. PMID: 36368038 Free PMC article. Clinical Trial.
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Peterson J, Drazan D, Czajka H, Maguire J, Pregaldien JL, Seppa I, Maansson R, O'Neill R, Balmer P, Jodar L, Jansen KU, Anderson AS, Perez JL, Beeslaar J. Peterson J, et al. Among authors: jodar l. Lancet Infect Dis. 2023 Dec;23(12):1370-1382. doi: 10.1016/S1473-3099(23)00191-3. Epub 2023 Aug 11. Lancet Infect Dis. 2023. PMID: 37579773 Clinical Trial.
Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT-PCR.
Ramirez J, Carrico R, Wilde A, Junkins A, Furmanek S, Chandler T, Schulz P, Hubler R, Peyrani P, Liu Q, Trivedi S, Uppal S, Kalina WV, Falsey AR, Walsh EE, Yacisin K, Jodar L, Gessner BD, Begier E. Ramirez J, et al. Among authors: jodar l. Infect Dis Ther. 2023 Jun;12(6):1593-1603. doi: 10.1007/s40121-023-00805-1. Epub 2023 May 6. Infect Dis Ther. 2023. PMID: 37148463 Free PMC article.
Real-world impact and effectiveness of MenACWY-TT.
Villena R, Kriz P, Tin Tin Htar M, Burman C, Findlow J, Balmer P, Jodar L. Villena R, et al. Among authors: jodar l. Hum Vaccin Immunother. 2023 Aug 1;19(2):2251825. doi: 10.1080/21645515.2023.2251825. Hum Vaccin Immunother. 2023. PMID: 37679903 Free PMC article. Review.
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.
Tartof SY, Aliabadi N, Goodwin G, Slezak J, Hong V, Ackerson B, Liu Q, Shaw S, Welsh S, Stern JA, Kapadia B, Spence BC, Lewnard JA, Davis GS, Aragones M, Dutro M, Chilson E, Gonzalez E, Hubler R, Chia B, Jodar L, Gessner BD, Begier E. Tartof SY, et al. Among authors: jodar l. JAMA Netw Open. 2024 Dec 2;7(12):e2450832. doi: 10.1001/jamanetworkopen.2024.50832. JAMA Netw Open. 2024. PMID: 39671195 Free PMC article.
155 results